Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 11, 2008. The report discloses a material change in GSK's investment portfolio involving a Swiss biopharmaceutical company.
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics for GSK. It focuses exclusively on a specific equity transaction:
- Target Company: Addex Pharmaceuticals Limited (Addex).
- Transaction Type: Acquisition of additional common shares in the open market.
- Shares Acquired: 5,496 shares.
- Price per Share: CHF 34.90.
- Total Holding Post-Transaction: 293,125 shares (5.0% of issued common share capital).
- Acquiring Entity: SR One, Limited (a wholly owned US-registered subsidiary of GSK).
Material Changes
GSK increased its ownership stake in Addex Pharmaceuticals Limited to exactly 5.0%. This threshold triggered a mandatory disclosure requirement under the rules of the SWX Swiss Exchange. The increase was achieved through the purchase of 5,496 additional shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies related to GSK's overall operations. The document is strictly a regulatory notification of a shareholding change.
Investor Verification Checklist
- Verify the current market price of Addex Pharmaceuticals Limited shares on the SWX Swiss Exchange.
- Confirm the total number of issued shares for Addex to validate the 5.0% ownership calculation.
- Review Addex's corporate filings for any related party transaction disclosures regarding GSK.
- Check subsequent GSK filings to determine if the stake in Addex was increased further or divested.